-
The British Journal of Dermatology Jul 1976A description of the clinical and biochemical course is given for a patient who developed haemolysis and methaemoglobinaemia following dapsone therapy in high dosage for...
A description of the clinical and biochemical course is given for a patient who developed haemolysis and methaemoglobinaemia following dapsone therapy in high dosage for 2 weeks.
Topics: Aged; Anemia, Hemolytic; Dapsone; Dermatitis Herpetiformis; Female; Foot Diseases; Gangrene; Humans; Methemoglobinemia; Toes
PubMed: 952745
DOI: No ID Found -
Antimicrobial Agents and Chemotherapy May 1997We studied the penetration of dapsone into the epithelial lining fluid (ELF) of sixteen human immunodeficiency virus type 1-infected patients who had received the drug... (Clinical Trial)
Clinical Trial
We studied the penetration of dapsone into the epithelial lining fluid (ELF) of sixteen human immunodeficiency virus type 1-infected patients who had received the drug at a dose of 100 mg twice weekly as primary prophylaxis for Pneumocystis carinii pneumonia. Bronchoscopy, bronchoalveolar lavage (BAL), and venipuncture were performed for each patient at a specific time after administration of the last dose of dapsone. Dapsone concentrations in plasma and BAL were determined by high-performance liquid chromatography. The apparent volume of ELF recovered by BAL was determined by using urea as an endogenous marker. The mean concentrations of dapsone in ELF at 2 h (five patients), 4 h (three patients), 12 h (two patients), 24 h (three patients), and 48 h (three patients) were 0.95, 0.70, 1.55, 0.23, and 0.45 mg/liter, respectively, while concentrations in plasma were 1.23, 0.79, 1.31, 0.83, and 0.18 mg/liter, respectively. Dapsone concentrations in ELF were 76, 79, 115, 65, and 291% of those observed in plasma at the same times, respectively. These data show that dapsone is well distributed into ELF and that a twice-weekly 100-mg prophylactic regimen results in sustained concentrations in this compartment.
Topics: Adult; Bronchoalveolar Lavage Fluid; Bronchoscopy; Chromatography, High Pressure Liquid; Dapsone; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pleura; Pneumonia, Pneumocystis
PubMed: 9145873
DOI: 10.1128/AAC.41.5.1077 -
Journal of the Indian Medical... Nov 1967
Topics: Adult; Dapsone; Female; Humans
PubMed: 5595773
DOI: No ID Found -
Antimicrobial Agents and Chemotherapy Jul 1994The safety and pharmacokinetics of weekly dapsone and weekly dapsone plus pyrimethamine were examined in adult patients with human immunodeficiency virus infection who... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
The safety and pharmacokinetics of weekly dapsone and weekly dapsone plus pyrimethamine were examined in adult patients with human immunodeficiency virus infection who were at risk for pneumocystis pneumonia because of a prior episode or a CD4+ T-cell count less than 250 cells per mm3. Groups of patients received 100, 200, and 300 mg of dapsone as a single weekly dose. The maximum tolerated dose of weekly dapsone was established as 200 mg per week in patients receiving at least 500 mg of zidovudine concomitantly. This dose of dapsone was then found to be well tolerated when combined with pyrimethamine at 25 mg. Further patients were randomized to dapsone at 200 mg or dapsone at 200 mg plus pyrimethamine at 25 mg once weekly. Twenty-six patients each were followed for a median of 33 weeks on dapsone alone and 45 weeks on the combination. Seven patients in each group withdrew because of toxicity. Five patients receiving dapsone developed documented pneumocystis pneumonia, while four and two patients receiving dapsone plus pyrimethamine developed documented and presumptive pneumocystis pneumonia, respectively. To evaluate the tolerability of a higher dose of pyrimethamine, 11 patients had their regimen changed to dapsone at 200 mg plus pyrimethamine at 75 mg, which was well tolerated by 10 of the patients for a median period of 11 weeks. The pharmacokinetics of dapsone and pyrimethamine were examined by using a population pharmacokinetic model. Decreases in the apparent volume of the peripheral compartment were observed when multiple-dose regimens of dapsone were compared with single-dose dapsone and when multiple-dose regimens of dapsone with pyrimethamine were compared with multiple-dose dapsone alone. When administered weekly, dapsone at 200 mg and dapsone at 200 mg with pyrimethamine at 25 mg are both well-tolerated regimens. This preliminary study suggests that the efficacy of these regimens in preventing pneumocystis pneumonia, however, may be less than that of trimethoprim-sulfamethoxazole.
Topics: AIDS-Related Opportunistic Infections; Adult; Biological Availability; Chromatography, High Pressure Liquid; Dapsone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pneumonia, Pneumocystis; Pyrimethamine
PubMed: 7979291
DOI: 10.1128/AAC.38.7.1580 -
Asian Pacific Journal of Allergy and... Jun 1983
Topics: Adolescent; Adult; Aged; Autoantibodies; Autoimmune Diseases; Child; Dapsone; Female; Humans; Male; Middle Aged; Pemphigoid, Bullous; Skin Diseases, Vesiculobullous
PubMed: 6398078
DOI: No ID Found -
Nature Sep 1972
Topics: Acetates; Dapsone; Humans; Isoniazid; Leprosy
PubMed: 4561960
DOI: 10.1038/239159a0 -
American Journal of Hematology Aug 1994
Topics: Adolescent; Adult; Aged; Dapsone; Female; Humans; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Treatment Outcome
PubMed: 8037195
DOI: 10.1002/ajh.2830460423 -
The Journal of Pediatrics May 1993We studied dapsone pharmacokinetics in eight children with compromised immune function who were receiving three different preparations. Peak serum concentration was less...
We studied dapsone pharmacokinetics in eight children with compromised immune function who were receiving three different preparations. Peak serum concentration was less than 0.25 microgram/ml after doses of an extemporaneous liquid preparation but ranged from 0.72 to 1.33 micrograms/ml after initial tablet or proprietary liquid doses and 1.48 to 2.48 microgram/ml during long-term proprietary liquid administration. Elimination followed first-order kinetics; the mean elimination half-life was 15.1 hours.
Topics: Biological Availability; Child; Child, Preschool; Dapsone; Female; Half-Life; Humans; Immunocompromised Host; Infant; Male
PubMed: 8496767
DOI: 10.1016/s0022-3476(06)80033-8 -
Indian Journal of Leprosy Jan 1988A case of suicide with dapsone is reported in a female medico chemical analysis report confirmed it to be death due to dapsone. Management in case of dapsone poisoning...
A case of suicide with dapsone is reported in a female medico chemical analysis report confirmed it to be death due to dapsone. Management in case of dapsone poisoning is also discussed.
Topics: Dapsone; Female; Half-Life; Humans; Suicide
PubMed: 3204280
DOI: No ID Found -
Leprosy Review Dec 1980
Topics: Animals; Dapsone; Drug Resistance, Microbial; Humans; Leprosy; Mali; Mice; Mycobacterium leprae
PubMed: 7012500
DOI: 10.5935/0305-7518.19800032